Legal & General Group
IMRX icon

Legal & General Group’s Immuneering IMRX Stock Holding History

Legal & General Group’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26K Buy
+5,203
New +$26.3K ﹤0.01% 3010
2024
Q2 		– Sell
-2,168
Closed -$6.27K – 3464
2024
Q1 		$6.27K Hold
2,168
– – ﹤0.01% 3271
2023
Q4 		$16K Sell
2,168
-476
-18% -$3.17K ﹤0.01% 3116
2023
Q3 		$20.3K Buy
2,644
+302
+13% +$2.78K ﹤0.01% 3021
2023
Q2 		$23.7K Buy
+2,342
New +$22.5K ﹤0.01% 3036
2022
Q3 		– Sell
-1,591
Closed -$9K – 3469
2022
Q2 		$9K Sell
1,591
-271
-15% -$1.45K ﹤0.01% 3382
2022
Q1 		$12K Buy
1,862
+1,088
+141% +$10.4K ﹤0.01% 3364
2021
Q4 		$13K Hold
774
– – ﹤0.01% 3402
2021
Q3 		$20K Buy
+774
New +$20.8K ﹤0.01% 3271

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Legal & General Group's IMRX Position: Q2 2026 in Review

Legal & General Group opened a new position in Immuneering (IMRX) in Q2 2026: 5,203 shares worth $26K. The stake represents ﹤0.01% of the portfolio and ranks #3010 among its holdings. This is a return to the name: Legal & General Group previously reported a position in IMRX as recently as Q1 2024.

Legal & General Group first reported a position in IMRX in Q3 2021 and has held it in 9 quarters since. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Legal & General Group held 5,203 shares of Immuneering worth $26K as of Q2 2026.
  • Immuneering was a new Legal & General Group position in Q2 2026.
  • Immuneering made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3010 holding.
  • Legal & General Group first reported a position in Immuneering in Q3 2021 and has held it in 9 quarters since.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.